Galectin Therapeutics Inc (GALT)

1.55
0.01 0.32
NASDAQ : Health Care
Prev Close 1.55
Open 1.58
Day Low/High 1.51 / 1.58
52 Wk Low/High 1.08 / 3.33
Volume 52.40K
Avg Volume 86.90K
Exchange NASDAQ
Shares Outstanding 28.98M
Market Cap 44.92M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Galectin Therapeutics Announces Positive Preclinical Results On The Role Of Galectin-3 In Mediating Vascular Remodeling In Pulmonary Arterial Hypertension

Galectin Therapeutics Announces Positive Preclinical Results On The Role Of Galectin-3 In Mediating Vascular Remodeling In Pulmonary Arterial Hypertension

Researchers at Augusta University show galectin-3 inhibitors improve PAH in animal models

Galectin Therapeutics Announces Complete Enrollment In Its Phase 2 Trial With GR-MD-02 In NASH Patients With Advanced Fibrosis

Galectin Therapeutics Announces Complete Enrollment In Its Phase 2 Trial With GR-MD-02 In NASH Patients With Advanced Fibrosis

Top line results of the NASH-FX trial to be reported in September 2016

Galectin Therapeutics Reports 2015 Financial Results And Provides Business Update

Galectin Therapeutics Reports 2015 Financial Results And Provides Business Update

Conference Call to Begin at 8:30 a.m. ET Today

Galectin Therapeutics Announces Dismissals Of Federal Securities Class Action And Shareholder Derivative Actions

Galectin Therapeutics Announces Dismissals Of Federal Securities Class Action And Shareholder Derivative Actions

United States District Court Dismisses Both Actions With Prejudice

Galectin Therapeutics Selected To Present At Cavendish Global Health Impact Forum

Galectin Therapeutics Selected To Present At Cavendish Global Health Impact Forum

Forum Uniquely Brings Together Leading Family Offices, Their Foundations and Sovereign Wealth Fund Representatives Seeking Impact Investment, Grant-Giving, and Philanthropy Opportunities Within Health and Life Sciences

Galectin Therapeutics' GR-MD-02 To Be Studied In Combination With Keytruda(R) In Patients With Metastatic Melanoma

Galectin Therapeutics' GR-MD-02 To Be Studied In Combination With Keytruda(R) In Patients With Metastatic Melanoma

Providence Cancer Center Submits IND for Phase 1b Trial

Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02

Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02

Proof-of-Concept Study to Determine Safety and Efficacy in 10 Patients With Moderate-to-Severe Plaque Psoriasis

Galectin Therapeutics Announces Start Of Phase 2 Clinical Trial With GR-MD-02 In NASH With Advanced Fibrosis

Galectin Therapeutics Announces Start Of Phase 2 Clinical Trial With GR-MD-02 In NASH With Advanced Fibrosis

Second Trial in GR-MD-02 Phase 2 Program Features Non-Invasive Endpoints and Shorter Treatment Duration; Data Readout Expected in the Third Quarter of 2016

Galectin Therapeutics Receives U.S. Patent Notice Of Allowance For Use Of Pectin Compounds To Reduce Fibrosis In Multiple Diseases

Galectin Therapeutics Receives U.S. Patent Notice Of Allowance For Use Of Pectin Compounds To Reduce Fibrosis In Multiple Diseases

Broad Coverage Includes Use of Various Pectin Compounds for Chronic Kidney Disease Associated with the Development of Fibrosis, Established Kidney Fibrosis, Chronic Lung Disease Associated with the Development of Fibrosis and Established Lung Fibrosis

Exalenz Bioscience Announces Collaboration With Galectin Therapeutics To Use BreathID® To Monitor Patients With Cirrhosis Associated With NASH

Exalenz Bioscience Announces Collaboration With Galectin Therapeutics To Use BreathID® To Monitor Patients With Cirrhosis Associated With NASH

Non-invasive BreathID test to be used to follow treatment effect of GR-MD-02 in Phase II Clinical Study